Complete Revascularization Via Inferior Part-sternotomy

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorChina National Center for Cardiovascular Diseases

About this trial

To verify the effectiveness and safety of minimally invasive coronary artery bypass grafting for complete revascularization of multivessel coronary artery disease via inferior part-sternotomy, We aim to randomize 260 patients undergoing isolated Coronary artery bypass grafting (CABG) to compare the ratios of complete revascularization between inferior part-sternotomy CABG and full median sternotomy CABG from 9 hospitals in China.

Eligibility criteria

Qualifiers

None

Disqualifiers

Single vessel disease, double vessel disease, left main artery disease without right coronary artery disease.

Concomitant cardiac surgeries(i.e. valve repair or replacement, Maze surgery, left ventricular repair due to ventricular aneurysm).

Redo CABG.

Emergent CABG.

Trial design

Treatments tested in this trial

  • Inferior part-sternotomy
  • Full median sternotomy

Treatment groups

260 Participants
are divided into 2 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

China National Center for Cardiovascular Diseases

Lead sponsor

Tangshan Central Hospital

Collaborator

Baotou Central Hospital

Collaborator

Xiamen Second Hospital

Collaborator

Beijing Shijitan Hospital, Capital Medical University

Collaborator

Peking University International Hospital

Collaborator

Shenzhen Sun Yat-sen Cardiovascular Hospital

Collaborator

Fuwai Yunnan Cardiovascular Hospital

Collaborator

Henan Provincial People's Hospital

Collaborator